Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity

免疫学 医学 环磷酰胺 人类白细胞抗原 CD19 Blinatumoab公司 HLA-B抗原 内科学 免疫系统 抗原 化疗
作者
Su Han Lum,Michael H. Albert,Patrick Gilbert,Tiarlan Sirait,Mattia Algeri,R. Muratori,Benjamin Fournier,Alexandra Laberko,Musa Karakükçü,Ekrem Ünal,Mouhab Ayas,Satya Prakash Yadav,Tunç Fışgın,Reem Elfeky,Juliana Folloni Fernandes,Maura Faraci,Theresa Cole,Ansgar Schulz,Roland Meisel,Marco Zecca,Marianne Ifversen,Alessandra Biffi,Jean‐Sébastien Diana,Tanja C. Vallée,Stefano Giardino,Gizem Zengin Ersoy,Despina Moshous,Andrew R. Gennery,Dmitry Balashov,Carmem Bonfim,Franco Locatelli,Arjan C. Lankester,Bénédicte Neven,Mary Slatter
出处
期刊:Blood [Elsevier BV]
被引量:2
标识
DOI:10.1182/blood.2024024038
摘要

HLA-mismatched transplants with either in vitro depletion of CD3+TCRαβ/CD19 (TCRαβ) cells or in vivo T-cell depletion using post-transplant cyclophosphamide (PTCY) have been increasingly used for patients with inborn errors of immunity (IEI). We performed a retrospective multicenter study via the EBMT registry on 306 children with IEI undergoing first transplant between 2010-2019 from an HLA-mismatched donor using TCRαβ (n=167) or PTCY (n=139). Median age at HSCT was 1.2 years (range, 0.03-19.6 years). The 3-year overall survival (OS) was 78% (95% confidence interval (CI), 71-84%) after TCRαβ and 66% (57-74%) after PTCY (p=0.013). Pre-HSCT morbidity score (hazard ratio (HR) 2.27, 1.07-4.80, p=0.032) and non-Busulfan/Treosulfan conditioning (HR 3.12, 1.98-4.92, p<0.001) were the only independent predictors of unfavorable OS. The 3-year event-free survival (EFS) was 58% (50-66%) after TCRαβ and 57% (48-66%) after PTCY (p=0.804). Cumulative incidence of severe acute GvHD was higher after PTCY (15%, 9-21%) than TCRαβ (6%, 2-9%, p=0.007), with no difference in chronic GvHD (PTCY, 11%, 6-17%; TCRαβ, 7%, 3-11%, p=0.173). The 3-year GvHD-free EFS was 53% (44-61%) after TCRαβ and 41% (32-50%) after PTCY (p=0.080). PTCY had significantly higher rates of veno-occlusive disease (14.4% versus TCRαβ 4.9%, p=0.009), acute kidney injury (12.7% versus 4.6%, p=0.032) and pulmonary complications (38.2% versus 24.1%, p=0.017). Adenoviraemia (18.3% versus PTCY 8.0%, p=0.015), primary graft failure (10%, versus 5%, p=0.048), and second HSCT (17.4% versus 7.9%, p=0.023) were significantly higher in TCRαβ. In conclusion, this study demonstrates that both approaches are suitable options in IEI patients, although characterized by different advantages and outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ma关注了科研通微信公众号
1秒前
1秒前
2秒前
畅快城发布了新的文献求助10
2秒前
复成完成签到 ,获得积分10
3秒前
yinle关注了科研通微信公众号
3秒前
aktuell完成签到,获得积分10
3秒前
3秒前
ANG发布了新的文献求助10
3秒前
Lucas应助2116564采纳,获得10
3秒前
量子星尘发布了新的文献求助10
4秒前
清辉夜凝发布了新的文献求助10
4秒前
可爱的函函应助Shrine采纳,获得10
5秒前
recovery应助Aprilapple采纳,获得10
6秒前
baonali发布了新的文献求助10
7秒前
123发布了新的文献求助30
7秒前
小晓发布了新的文献求助10
7秒前
科研通AI2S应助Andema采纳,获得10
7秒前
9秒前
9秒前
12秒前
12秒前
14秒前
李健应助假发君采纳,获得10
15秒前
16秒前
KIORking发布了新的文献求助10
16秒前
落忆发布了新的文献求助10
16秒前
tengfei完成签到 ,获得积分10
16秒前
yinle发布了新的文献求助10
17秒前
17秒前
Ma发布了新的文献求助10
17秒前
17秒前
shensiang完成签到,获得积分10
18秒前
2116564发布了新的文献求助10
18秒前
19秒前
DZ完成签到,获得积分10
20秒前
俏皮小土豆完成签到,获得积分10
20秒前
Shrine发布了新的文献求助10
22秒前
炸胡娃娃完成签到,获得积分10
22秒前
清爽笑翠完成签到 ,获得积分10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989444
求助须知:如何正确求助?哪些是违规求助? 3531531
关于积分的说明 11254250
捐赠科研通 3270191
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174